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Abstract
Ibuprofen is one of the most potent orally active antipyretic, analgesic and non-steroidal anti-inflammatory drug (NSAID) used extensively in the 
treatment of acute and chronic pain, osteoarthritis, rheumatoid arthritis and related conditions. This compound is characterized by a better 
tolerability compared with other NSAIDs. This study aimed at evaluating some quality control parameters to compare the quality, safety, and 
efficacy of three brands of ibuprofen tablets available in the Indian market. The organoleptic and physicochemical properties of three brands of 
ibuprofen tablets were assessed according to established methods. The ibuprofen tablet, brand Q exhibited highest dissolution efficiency up to 
30 min (48.68±1.24) and lowest mean dissolution time (3.32±0.06) compared to other tablets. Moreover, this branded tablet showed highest 
% of drug content (99.21±0.17) compared to other tablets.
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Introduction
The relief of pain has been described as a universal human right but 
1 is not always easily achieved.  Opioid analgesics are effective, but 
have troublesome and potentially dangerous side-effects, and their 
potential for abuse may lead to regulatory and logistical difficulties. 
Non-steroidal  anti-inflammatory  drugs  (NSAIDs)  have  fewer 
regulatory restrictions, but they too have important adverse effects 
2 which  are  more  likely  at  higher  dose  or  with  longer  courses.  
NSAIDS are a group of unrelated organic acids that mostly affect 
3 gastrointestinal  tract  (GIT).  Dyspeptic  complaints,   upper  GI 
4 5-7 bleeding,  and mucosal and duodenal ulcers,  are common adverse 
drug  reaction  associated  with  this  group  and  may  be  life 
8 threatening.  In 2002, Aletaha found that about 72% of the patients 
with  rheumatoid  arthritis  treated  with  NSAIDs  received 
gastrointestinal  (GI)  protective  therapy  mainly  with  histamine 
9 antagonists and sucralfate.  Due to gastrointestinal side effects, the 
health  and  economic  burdens  related  to  these  drugs  are 
1 considerable.  A distinct relationship between effects and side 
effects exists, namely, rapid absorption beginning in the stomach in 
associated  with  intensive  gastric-duodenal  irritation  and 
11 ulceration.  Epidemiological studies have clearly demonstrated a 
rank order of risk of ulcer complication for commonly used NSAIDs, 
12-13 with ibuprofen consistently associated with the lowest risk.
Ibuprofen  is  the  most  commonly  used  and  most  frequently 
14-15 prescribed NSAID.  It was the first member of propionic acid 
derivatives to be introduced in 1969 as a better alternative to 
Aspirin (Fig. 1). Gastric discomfort, nausea and vomiting though 
less than aspirin or indomethacin, are still have most common side 
16 effects.
It  is  non-selective  inhibitor  of  cyclooxygenase-1(COX-1)  and 
17 cyclooxygenase-2(COX-2).   Although  its  anti-inflammatory 
properties may be weaker than those of some other NSAIDs, it has 
a prominent analgesic and antipyretic role. Its effects are due to the 
inhibitory actions on cyclooxygenase, which are involved in the 
synthesis of prostaglandins. Prostaglandins have an important role 
18 in the production of pain, inflammation, and fever.
19 Ibuprofen is supplied as tablets with a potency of 200 to 800 mg.  
20 The usual dose is 400 to 800 mg three times a day.   It is almost 
21 insoluble in water having pKa of 5.3.  It is well absorbed orally; 
peak serum concentrations are attained in 1 to 2 h after oral 
administration. It is rapidly bio-transformed with a serum half-life 
of 1.8 to 2 h. The drug is completely eliminated in 24 h after the last 
22-23 dose and eliminated through metabolism.  The drug is more than 
99% protein bound, intensively metabolized in the liver and is 
24 excreted unchanged.
Post  market  surveillance  or  monitoring  involves  all  activities 
undertaken to obtain more data and information about a product 
after  it  had  been  granted  marketing  authorization  and  made 
available for public use. The data and information so obtained could 
be employed for product improvement, development of standards 
and regulations. Regulatory agencies rely on limited information 
obtained  during  clinical  trials  and  to  some  extent  scientific 
literature  as  guides  to  granting  marketing  authorization  of 
medicines for public use. It is therefore imperative to conduct post-
market surveillance or monitoring of approved medicines in order 
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where, W  is the initial weight and W  represents final weight. 1 2
Hardness testing
The  crushing  strength  of  the  tablets  was  determined  using  a 
Monsanto tablet hardness tester (Monsanto, Rolex tablet Hardness 
tester, Labtech, India).
to adequately assess the quality therapeutic effectiveness and 
safety of medicines for the larger public. The aim of this study was 
to compare the physicochemical parameters and assay of the three 
brands of ibuprofen tablets.
Materials and Methods
Materials
Ibuprofen brands having label strength of 400 mg (Table 1) were 
purchased from a retail pharmacy in Bhilai, Chhattisgarh, India. All 
tests were performed within product expiration dates. The reagents 
used were potassium dihydrogen phosphate, sodium hydroxide, 
hydrochloric  acid  were  obtained  commercially  and  used  as 
received.
Determination of drug content 
The  tablets  were  finely  powdered  and  a  quantity  of  powder 
equivalent to 100 mg of ibuprofen were accurately weighed and 
transferred  to  100  ml  of  buffer  solution  (pH  7.2)  and  mixed 
thoroughly. The solutions were filtered, diluted with buffer solution 
(pH 7.2), and analyzed for the content of ibuprofen using UV-visible 
spectrophotometer (UV-1800 Shimadzu, Japan) at 221 nm. The 
drug content of each sample was estimated from their previously 
25 prepared standard curve.
Uniformity of weight
The variation of the weight of individual tablets is a valid indication 
26 of the corresponding variation in the drug content . The average 
tablet weight was determined by weighing 20 tablets individually 
using  a  digital  analytical  balance  (Denver  Instrument,  TB  214, 
India). 
Thickness and diameter measurement
20  tablets  were  taken  and  their  thickness  and  diameter  were 
determined  individually  by  Vernier  caliper  (China).  Mean  and 
standard deviation were calculated.
Friability Test
Twenty tablets were weighed and subjected to friability test using a 
Roche Friabilator (India). After the given number of rotations (100 
rotations/4 min) loose dust was removed from the tablets. Finally 
tablets were weighed. The loss in weight indicates the ability of the 
27 tablets to withstand this type of wear.  The percent friability was 
determined by using following formula:
Disintegration test
Disintegration time of six tablets per brand was determined in 
o distilled water maintained at 37±0.5 C using tablet disintegration 
apparatus (Lab Hosp, India). The disintegration time was taken to 
be the no particle remained on the basket of the system.
Preparation of standard calibration curve for Ibuprofen in 
phosphate buffer (pH 7.2)  
10 mg of ibuprofen was taken in a 100 ml volumetric flask and 
makes up the volume with phosphate buffer (pH 7.2) and named it 
stock solution, its concentration was 0.1 mg/ml. From the above 
solution  0.1,  0.2,  0.4,  0.6,  0.8  and  1  ml  was  taken  in  10ml 
volumetric flask and makes up the volume. Its concentration was 
1, 2, 4, 6, 8, 10 μg/ml. Absorbance of the sample was taken at 
221nm in a UV-visible spectrophotometer (UV-1800 Shimadzu, 
Japan). The average values of absorbance were plotted against 
respective concentrations (Fig. 2).
Dissolution test
Dissolution profiles of the ibuprofen tablets were determined in 
o USP phosphate buffer solution (900 ml, pH 7.2, 37±0.5 C) using 
USP II dissolution test apparatus (TDL-08L, India). At appropriate 
time intervals, 5 ml samples were withdrawn and replenished 
with the same volume of fresh medium. The aliquots following 
suitable dilution were analyzed spectrophotometrically at 221 nm.
Statistical analysis
The differences in physicochemical properties were evaluated by 
one-way analysis of variance using Graph Pad Instat software. 
Differences were considered significant when p< 0.05.
Results and Discussion
Three ibuprofen brands having label strength of 400mg were 
purchased from a local retail pharmacy (India). All tests were 
performed within product expiration dates during study period. 
The compendia standards are weight variation, drug content, 
disintegration  time,  and  dissolution,  whereas  hardness  and 
friability are non compendia standards. However, friability is now 
included  in  the  United  State  Pharmacopeia  (USP,  1995).  The 
uniformity of weight determination for three brands of ibuprofen 
tablets gave values that are within limits. There was different 
mean weight of all brands because of different excipient used in 
the  different  brands.  For  consumer  requirement  and  also  for 
packaging of tablets thickness and diameter parameters are also 
necessary for uniformity of tablets. The thickness and diameter of 
ibuprofen tablets were found to be within their permissible limit 
(± 5%) (Table 2).
For assurance of uniform potency of tablets, weight variation is 
not sufficient. The potency of tablets is expressed in terms of 
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gram, milligrams, or micrograms of drug per tablet and is given as 
the label strength of the product. The BP specification is that the 
content of drug should not be less than 95% and not more than 
105%. The potency of tablets was found to be 97.74 - 99.21% (Table 
3). The result ascertains the presence and compendia quantity of 
ibuprofen  in  all  the  brands  and  so  could  not  be  judged  as 
counterfeits without active pharmaceutical ingredients. However, 
statistically significant difference (p <0.05) of drug content was 
observed in different tablet brands. The hardness of the tablets is an 
essential criterion in the determination of the ability of the tablets to 
resist chipping, abrasion, or breakage under conditions of storage, 
transportation, and handling. The hardness of the tablet was found 
2 to be 5.56-5.73 kg/cm  (Table 3). Brand R required least pressure 
before fracture while brand Q required highest pressure. The result 
of analysis of variance revealed significant difference (p< 0.05) in 
hardness of all the three brands at 95% confidence interval. This 
indicated that the tablet can withstand the rigors of transportation 
and handling. Another measure of tablet strength, its friability is 
often  measured  because  tablet  hardness  is  not  an  absolute 
parameter of strength since some tablets tend to cap on attrition, 
losing  their  crown  portions  when  compressed  into  very  hard 
tablets.  The  Pharmacopoeia  (USP  30,  NF  25)  states  that  the 
friability value of tablets should be less than 1% and as such all the 
brands of ibuprofen had passed this friability specification 0.05-
0.1% (Table 3). Analysis of variance revealed significant difference 
in friability (F  < F  at 95% level) of all branded tablets.  calculated tabular
Different formulation factors are known to be affect results of 
disintegration  test.  The  disintegration  test  measures  the  time 
required for a tablet to disintegrate into particles when in contact 
with gastrointestinal fluids. This is necessary condition and could 
be the rate- determining step in the process of drug absorption. The 
type and amount of excipient used in tablet formulation as well as 
manufacturing process are all known to affect the disintegration. 
The BP 2003 stipulates a disintegration time of not less than 15 min 
for  uncoated  tablets  and  30  minutes  for  coated  tablets.  The 
disintegration  time  of  coated  ibuprofen  400mg  tablets  was 
determined according to USP 2007. Film coated tablets pass the 
disintegration test if each of six tablets disintegrate in not less than 
30 minutes in simulated gastric fluid. The result of the disintegration 
test is presented in Table 3. Result indicates that all brands of 
ibuprofen tablet passed the disintegration test. However, analysis 
of variance revealed significant difference in disintegration time 
(F  > F  at 95% level) of branded tablets. calculated tabular
Dissolution of drug from oral solid dosage form is a necessary 
criterion for drug bioavailability (i.e., the drug must be solubilized in 
the aqueous environment of gastrointestinal tract to be absorbed). 
For this reason, dissolution testing of solid oral drug products has 
emerged assuring product uniformity. The results of dissolution 
tests in terms of dissolution efficiency and time to dissolve 50%  
drug (t ) and 85% (t ) drug and mean dissolution time are shown  50% 85%
in Table 4. Mean dissolution time (MDT) reflects the time for the 
drug  to  dissolve  and  is  the  first  statistical  moment  for  the 
cumulative dissolution process that provides an accurate drug 
release profile. A higher mean dissolution time value indicates 
greater  drug  retarding  ability.  MDT  was  calculated  from  the 
following equation:
ú
ú
ú
ú
û
ù
ê
ê
ê
ê
ë
é
D
D ´
=
å
å
=
=
n
i
n
i
mid
M
M t
MDT
1
1
where i = dissolution sample numbers, n = number of dissolution 
times, t = time at the midpoint between times t and t ,   M =  mid i i-1
amount of drug dissolved between times t and t .The release  i i-1 
profiles of the drug from various tablets are shown in Fig. 3. The 
dissolution  efficiency  (DE)  is  defined  as  the  area  under  the 
dissolution curve up to a certain time, t, expressed as a percentage 
of the area of the rectangle described by 100% dissolution in the 
28 same time.  DE was calculated from the following equation;
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Where, y is the drug percent dissolved in the time t. 
Dissolution efficiency (DE) can have a range of values depending 
on the time interval chosen. However, while comparing a set of 
data a constant time interval should be selected. In the present 
study,  DE   min  (Dissolution  efficiency  up  to  30  min)  were  30
calculated from the dissolution profile of three brands of ibuprofen 
tablets and used for comparison. The time required for 50% (t ) of  50%
drug dissolution ibuprofen from three brands of ibuprofen tablets P, 
Q and R were found to be 20.11, 13.93 and 15.46 min, respectively. 
Similarly, time required for 85% (t ) of drug dissolution were found  85%
to be 43.84, 26.67, 35.87 min respectively (Table 4). Dissolution 
efficiency curve of tablets are presented in Fig. 4. From dissolution 
efficiency profile, it was observed that the dissolution efficiency 
increased in the following order P<R<Q.
 
CH3
O H
CH3
O
Fig.1: Structure of ibuprofen
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Table 1. Label information on the Ibuprofen tablets evaluated
Code Brand name Batch No. Manufacture
date
Expiry 
date
Labeled strength
(mg)
Manufacture
P
Q
R
Ibuprofen 400
Brufen 400
Ibugesic 400
4188
B– 411B
AO 2971
Nov 2010
Sep 2009
Dec 2010
Oct 2012
Aug 2012
Nov 2013
400
400
400
Vikram Laboratories (P) LTD.
Abbott India Limited
Cipla LTD
Table 4. Characteristics of ibuprofen tablets 
P
Q
R
Code t   50%
(Mean ± SD, n= 3)
t   85%
(Mean ± SD, n= 3)
MDT
(Mean ± SD, n= 3)
20.11 ± 1.04
13.93 ± 0.27
15.46 ± 1.23
43.84 ± 0.97
26.67 ± 1.23
35.87 ± 6.11
4.33 ± 0.11
3.32 ± 0.06
3.92 ± 0.19
Table 2. Weight variation, thickness, and diameter of ibuprofen tablet
Code Weight (mg)
(Mean ± SD, n= 20)
Thickness (mm)
(Mean ± SD, n= 20)
Diameter (mm)
(Mean ± SD, n= 20)
P
Q
R
0.515 ± 0.010
0.557 ± 0.011
0.571 ± 0.005
5.613 ± 0.099
5.747 ± 0.070
5.876 ± 0.033
12.428 ± 0.023
14.122 ± 0.030
14.120 ± 0.025
Table 3. Drug content, hardness, friability, and disintegration time of branded tablets
Code Drug content (%)
(Mean ± SD, n= 3)
2 Hardness (Kg/cm )
(Mean ± SD, n= 3)
Friability (%)
(Mean ± SD, n= 6)
Disintegration time 
in simulated gastric 
fluid (Mean ± SD, 
n= 6)
97.74 ± 0.54
99.21 ± 0.11
98.70 ± 0.17
P
Q
R
5.566 ± 0.11
5.733 ± 0.20
5.333 ± 0.06
0.11 ± 0.06
0.05 ± 0.02
0.08 ± 0.03
32.00±1.26
34.00±0.89
33.83±1.16
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Conclusion
In this study three brands of ibuprofen tablets evaluated and could 
be evaluated as being pharmaceutically and chemically equivalent 
and can be freely interchanged. The ibuprofen tablet, brand Q 
exhibited highest DE up to 30 min (48.68 ± 1.24) and lowest MDT 
(3.32 ± 0.06) compared to other tablets. Moreover, this branded 
tablet showed highest % of drug content (99.21 ± 0.17) compared 
to other tablets. This study highlights the need for constant market 
monitoring  of  new  products  to  ascertain  their  equivalency  to 
official standards.   
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